Brand dynamics

Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health

Innovation and Quality Improvement: Healthy Element Focuses on Innovative Drugs and High-Barrier Complex Formulations R&D to Achieve High-Quality Development

Published Time:

2024-07-12

The innovative drug industry is receiving another policy boost. On July 5, the State Council executive meeting reviewed and approved the "Implementation Plan for Supporting the Development of Innovative Drugs Across the Entire Chain," marking a transition for China's domestic innovative drug industry from the research and development investment stage to the value realization stage.

 

In recent years, scientific research and innovation have become the main development focus of the pharmaceutical industry, and also the lifeline for pharmaceutical companies to achieve sustainable and high-quality development. Innovative drugs, as one of the representative industries of new productive forces, have also received key national support. Many pharmaceutical companies are accelerating their investment in the innovative drug sector, aiming to improve quality through innovation and drive further innovation through quality. Improving quality through innovation and driving further innovation through quality.

 

Established in 1992, HealthGen, with innovation and R&D as its core, has always focused on the greater health field. From its early layout in the inhaled formulation field to its increased investment in the innovative drug sector, the company's development strategy is clear and forward-looking.

 

In 2013, HealthGen established Shanghai Fanyu to focus on the inhaled formulation field, becoming one of the earliest companies in China to do so; in 2019, the company established a high-end complex formulation technology platform, with the inhaled formulation platform standing out; in 2022, HealthGen accelerated its layout in innovative drugs, building an innovative drug and high-barrier complex formulation platform.

 

HealthGen has always focused on its advantageous respiratory formulation field, seizing the industry's development trends and building the company's differentiated competitive barriers.

 

The company adheres to scientific research and innovation as its core driving force. In 2023, HealthGen's R&D expenses reached 1.662 billion yuan, and the continuous high investment in R&D has yielded significant results for the company. By the end of 2023, HealthGen had a total of 1,008 valid patent authorizations, including 521 invention patents.

 

From 2018 to the present, HealthGen has focused on and cultivated innovative, high-barrier formulation R&D platforms, including inhaled formulations and the monoclonal antibody and sustained-release microsphere platforms of its holding subsidiary, Lizhu Group. Relying on innovative and high-barrier formulation technology platforms, the company has achieved a first-mover advantage in relevant sub-sectors, with multiple products breaking foreign monopolies in the industry.

 

In the advantageous respiratory field, the number of HealthGen's respiratory pipeline products launched by the end of last year increased to 8 varieties and 12 specifications. The latest data from Pharma Intelligence shows that HealthGen is one of the top three manufacturers of inhaled formulations in China. In 2023, HealthGen achieved sales revenue of 1.741 billion yuan in the respiratory sector, a year-on-year increase of approximately 48.35%. Respiratory formulation products cover more than 4,000 secondary and above-level hospitals.

 

In the past two years, HealthGen has accelerated its layout in the innovative drug sector, efficiently advancing the R&D and clinical development progress of existing innovative drugs, building a differentiated product pipeline layout, and accelerating the formation of the company's new productive forces. Currently, the company's main innovative drugs under development have expanded from the respiratory field to multiple fields such as analgesia, digestive system, cardiovascular and mental diseases.

 

With its solid innovative R&D capabilities and comprehensive drug R&D pipeline layout, HealthGen was ranked by MiNet among the top 10 Chinese chemical pharmaceutical companies in 2023, and was also ranked 25th on Pharma Intelligence's 2024 China Chemical Pharmaceutical R&D Strength Ranking and 47th on the 2024 China Pharmaceutical R&D Comprehensive Strength Ranking; its holding subsidiary, Lizhu Group, also successfully made the list of Pharma Intelligence's two R&D rankings, ranking 27th and 42nd respectively.

 

It is worth noting that while focusing on R&D and multi-dimensional product layout, HealthGen actively shares the dividends of its continuous development with its shareholders. According to the 2023 dividend distribution plan, HealthGen plans to distribute a cash dividend of RMB 1.80 per 10 shares (including tax) to all shareholders.

 

In addition to dividends, the company has also conducted several share buybacks in recent years. In 2023, HealthGen repurchased shares totaling 475 million yuan through concentrated bidding, which is considered equivalent to cash dividends. Together with the planned dividend distribution, HealthGen's total cash dividend in 2023 amounted to 811 million yuan, accounting for 56.22% of the net profit attributable to shareholders of the listed company in the consolidated financial statements for the reporting period.

 

Some professionals believe that cash dividends are an important way for investors to obtain returns, and are also an important way to cultivate investors' long-term investment philosophy and enhance the attractiveness of the capital market. Since its listing, HealthGen has maintained a stable dividend policy. To date, the company has distributed cash dividends 19 times, with a cumulative dividend amount exceeding 3.2 billion yuan, demonstrating the company's emphasis on shareholder interests and confidence in future development.

 

In the future, HealthGen will further implement its "innovative drugs + high-barrier complex formulations" dual-engine drive strategy, implement a differentiated R&D layout, use innovation to accelerate the development of new productive forces, lay a solid foundation for stability and accumulate momentum for innovation, and promote the company's high-quality development through technological breakthroughs and innovation in production factors.


This article is from: Everycn.com